OBI Pharma Inc (浩鼎) yesterday gained shareholders’ approval to issue new shares to fund its long-term development, clinical trial and diversification plans.
The biotech company received authorization to issue no more than 15 million new shares to raise between NT$3 billion and NT$4 billion (US$98.51 million and US$131.35 million) at its annual general meeting in Taipei.
In light of its depressed stock price, fundraising would take place over the next one or two years, the company said, adding that it is considering either a capital injection through a private placement or in conjunction with issuance of depositary receipts abroad.
The company said that while its cash balance of NT$4.2 billion is enough to sustain operations through 2020, additional funding would be required by then, when a number of projects are expected to progress to phase two clinical trials.
OBI Pharma shares yesterday dipped 0.32 percent to NT$157.50 in Taipei trading.
The stock was trading above NT$681 in 2016, before tumbling after phase two and three clinical trials showed no statistical significance in proving the effectiveness of its breast cancer drug OBI-222.
The company and its executives have since been embroiled in insider trading allegations, sending a shockwave through the nation’s biotechnology sector.
Following the setback, the company is set to begin enrolling patients for a redesigned phase three clinical trial for the drug in the US, president Amy Huang (黃秀美) said.
The redesigned clinical study expanded enrollment criteria, making it available to a larger number of patients who are in varying stages of treatment and disease progression, Huang said.
In particular, triple-negative breast cancer patients with a higher level of expression of Globo H, which the drug — renamed Adagloxad Simolenin — is designed to target and trigger an immune system response.
The enrollment process would take place over the next two years, followed by three years of primary endpoint study and another two years survival analysis, Huang said.
The company will continue to devote funds to diversify its development pipeline, chairman Michael Chang (張念慈) said.
It is collaborating with AP Biosciences (圓祥生技) on OBI-3424, a first-in-class DNA alkylating agent that targets cancers that overexpress the aldo-keto reductase 1C3 enzyme, which is part of efforts to explore new territories in immune checkpoint inhibitors and bi-specific antibodies, as well as liver cancer treatments, Chang said.
While the company has been vindicated after Taipei prosecutors in February dropped insider trading charges against former Academia Sinica president Wong Chi-huey (翁啟惠) and OBI Pharma executives, the judicial process has taken its toll on operations, Chang and Huang said.
Chang added that he is confident that he would receive a favorable court ruling on other charges in September.
SEMICONDUCTORS: The German laser and plasma generator company will expand its local services as its specialized offerings support Taiwan’s semiconductor industries Trumpf SE + Co KG, a global leader in supplying laser technology and plasma generators used in chip production, is expanding its investments in Taiwan in an effort to deeply integrate into the global semiconductor supply chain in the pursuit of growth. The company, headquartered in Ditzingen, Germany, has invested significantly in a newly inaugurated regional technical center for plasma generators in Taoyuan, its latest expansion in Taiwan after being engaged in various industries for more than 25 years. The center, the first of its kind Trumpf built outside Germany, aims to serve customers from Taiwan, Japan, Southeast Asia and South Korea,
Gasoline and diesel prices at domestic fuel stations are to fall NT$0.2 per liter this week, down for a second consecutive week, CPC Corp, Taiwan (台灣中油) and Formosa Petrochemical Corp (台塑石化) announced yesterday. Effective today, gasoline prices at CPC and Formosa stations are to drop to NT$26.4, NT$27.9 and NT$29.9 per liter for 92, 95 and 98-octane unleaded gasoline respectively, the companies said in separate statements. The price of premium diesel is to fall to NT$24.8 per liter at CPC stations and NT$24.6 at Formosa pumps, they said. The price adjustments came even as international crude oil prices rose last week, as traders
POWERING UP: PSUs for AI servers made up about 50% of Delta’s total server PSU revenue during the first three quarters of last year, the company said Power supply and electronic components maker Delta Electronics Inc (台達電) reported record-high revenue of NT$161.61 billion (US$5.11 billion) for last quarter and said it remains positive about this quarter. Last quarter’s figure was up 7.6 percent from the previous quarter and 41.51 percent higher than a year earlier, and largely in line with Yuanta Securities Investment Consulting Co’s (元大投顧) forecast of NT$160 billion. Delta’s annual revenue last year rose 31.76 percent year-on-year to NT$554.89 billion, also a record high for the company. Its strong performance reflected continued demand for high-performance power solutions and advanced liquid-cooling products used in artificial intelligence (AI) data centers,
SIZE MATTERS: TSMC started phasing out 8-inch wafer production last year, while Samsung is more aggressively retiring 8-inch capacity, TrendForce said Chipmakers are expected to raise prices of 8-inch wafers by up to 20 percent this year on concern over supply constraints as major contract chipmakers Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and Samsung Electronics Co gradually retire less advanced wafer capacity, TrendForce Corp (集邦科技) said yesterday. It is the first significant across-the-board price hike since a global semiconductor correction in 2023, the Taipei-based market researcher said in a report. Global 8-inch wafer capacity slid 0.3 percent year-on-year last year, although 8-inch wafer prices still hovered at relatively stable levels throughout the year, TrendForce said. The downward trend is expected to continue this year,
RSS